ZW209 — IND submission
in 2026
We anticipate submitting an IND to commence Phase 1 clinical studies for ZW209 in 2026, with equivalent non-U.S. applications to be submitted thereafter.Source filing
ZYME biotech catalysts & pipeline
ZYMEWORKS INC · Data as of 2026-10-25
Upcoming catalysts
ZW1528 — IND submission
in 2027
We anticipate submitting a regulatory filing to commence Phase 1 clinical studies for ZW1528 in 2027.Source filing
EmpowHER-303 — Topline data
Sep 2027–Apr 2028
The EmpowHER-303 trial is expected to complete patient enrollment in mid-2027 with top-line data expected by the end of 2027 or early 2028.Source filing
pasritamig — Conference presentation
H2 2026
Johnson and Johnson Innovative Medicine (J&J) expect to present Phase 1b clinical data for pasritamig, a first-in-class bispecific antibody against KLK2, in combination with JNJ-9401 in patients with advanced prostate cancer who have progressed after multiple lines of therapy, during the second half of 2026.Source filing
zanidatamab — Topline data
Q3 2026
The top-line results from the second interim overall survival analysis for the HERIZON-GEA-01 trial doublet regimen are expected in the third quarter of 2026.Source filing